The company developed an antibody discovery platform to search blood samples of people who have recovered from COVID-19. In a collaboration with the U.S. National Institutes of Health, it has identified more than 500 anti-SARS-CoV-2 antibodies since February 25.

Under phase I of the Canadian collaboration, AbCellera will improve its antibody discovery platform for finding COVID-19 antibodies, while under phase II, it will build a new good manufacturing practice (GMP) facility in Vancouver to produce antibodies from patient samples for clinical trials.

AbCellera recently announced a partnership with Eli Lilly to develop a COVID-19 treatment, with clinical trials beginning in July, it said.

Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...

Valo to develop pancoronavirus vaccine
Valo Therapeutics announced that it is working on the development of a potential COVID-19 vaccine with applications across future pandemics.

WHO cautions against coronavirus 'immunity passports'
The World Health Organization (WHO) has published a report expressing caution about the value of antibody tests for the novel coronavirus and saying that...

Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene...

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...